Mesothelin Detection Service

Mesothelin is a protein expressed in a variety of tumors, and it is used as a potential biomarker in a variety of tumor research. Creative BioMart Biomarker provides customers with mesothelin rapid test service and ensures the accuracy and repeatability of test results. This testing service is only for research purposes, not for personal medical and diagnostic use.

Mesothelin Testing
Analyte: Mesothelin
Synonyms: MSLN
Sample Type: serum, plasma, cell culture supernatants, tissue homogenate or other biological fluids
Assay Platform: ELISA, CLIA
Biomarker Application Area: ovarian cancer
* Perform three replicate tests on each sample, and include appropriate controls in each assay.

Assay Background


Schematic of mesothelinFigure 1. Schematic of mesothelin (Hassana, et al. 2008)

Mesothelin is a glycophosphatidylinositol (GPI)-linked cell-surface glycoprotein, which is only expressed in mesothelial cells lining the pleura, pericardium and peritoneum in healthy people. Mesothelin is first synthesized as its precursor protein (71 kDa), and then the N-terminal megakaryocyte potentiating factor (MPF) is cleaved by the furin to form mature mesothelin (41 kDa). Mesothelin is expressed in a variety of tumors, and studies have suggested that its high expression level is related to the prognosis of ovarian cancer, breast cancer, cholangiocarcinoma, etc. The combination of mesothelin and ovarian cancer antigen MUC16 (also known as cancer antigen 125, CA-125) may induce cell adhesion, which may be involved in the tumor metastasis mechanism of ovarian cancer. In addition, Wnt-1 and Wnt-5a proteins, which play an important role in intracellular signal transduction, are involved in the regulation of mesothelin expression, while ovarian cancer, mesothelioma, and pancreatic cancer all have constitutive activation of Wnt signaling. Compared with healthy people, mesothelin has higher serum levels in mesothelioma and ovarian cancer patients, so mesothelin may be a potential diagnostic biomarker for mesothelioma and ovarian cancer.

Workflow of Biomarker Detection at Creative BioMart Biomarker

Workflow

Customers provide: samples, reagents/kits (reagents/kits can also be provided or purchased by our company).

We provide: remaining samples and reagents, complete experimental reports (including experimental raw data, experimental procedures, instrument and reagent information, and professional result analysis).

Test cycle: 10 working days or less.

Why Choose Creative BioMart Biomarker for Mesothelin Detection Service?

  • High-quality technology platform
  • Creative BioMart Biomarker provides two technology platforms for mesothelin testing, ELISA and CLIA. For the detection of biomarkers, our experts have optimized the technology platform to improve the sensitivity and specificity of the detection.

  • Experienced experts team
  • Our experts have extensive experience in biomarker testing, and will perform each test in full accordance with standard experimental operating procedures to ensure that the test results delivered are accurate and repeatable.

  • Suitable for multiple sample types
  • Our biomarker testing service is applicable to several sample types, including serum, plasma, cell culture supernatant, tissue homogenate, etc. If your sample type is not common, you can contact us at any time to inquire about the testing service for your sample.

  • Fast testing and reasonable price
  • We have been committed to providing customers with efficient services to ensure that the experimental results are delivered within the predetermined time. Our testing services have reasonable and competitive prices in the industry, which can help customers reduce research costs.

If you are interested in our services, please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.

References:

  1. Hassana, R.; Hob, M. Mesothelin targeted cancer immunotherapy. European Journal of Cancer. 2008, 44(1): 46-53.
  2. Hassana, R.; et al. Mesothelin immunotherapy for cancer: ready for prime time? Journal of Clinical Oncology. 2016, 34(34): 4171–4179.
Menu
Contact Us
Subscribe

Enter your email here to subscribe